Login to Your Account



ADA 2012 Scientific Sessions

Harmony 6,7 Detailed Results in Tune with Mixed Top-Line Data

By Catherine Shaffer
Staff Writer

Tuesday, June 12, 2012

Detailed results from GlaxoSmithKline plc's Harmony 6 and Harmony 7 Phase III trials of albiglutide in Type II diabetes at 52 and 32 weeks presented at the American Diabetes Association Meeting in Philadelphia showed mixed results compared to positive top-line Harmony 6 results previously reported, and results consistent with a previously reported primary endpoint miss for Harmony 7.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription